CDXS
Price
$2.46
Change
+$0.02 (+0.82%)
Updated
Jul 1, 02:26 PM (EDT)
Capitalization
202.14M
30 days until earnings call
NTLA
Price
$9.98
Change
+$0.60 (+6.40%)
Updated
Jul 1, 02:45 PM (EDT)
Capitalization
970.58M
30 days until earnings call
Interact to see
Advertisement

CDXS vs NTLA

Header iconCDXS vs NTLA Comparison
Open Charts CDXS vs NTLABanner chart's image
Codexis
Price$2.46
Change+$0.02 (+0.82%)
Volume$400
Capitalization202.14M
Intellia Therapeutics
Price$9.98
Change+$0.60 (+6.40%)
Volume$375
Capitalization970.58M
CDXS vs NTLA Comparison Chart in %
Loading...
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
View a ticker or compare two or three
VS
CDXS vs. NTLA commentary
Jul 01, 2025

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is CDXS is a StrongBuy and NTLA is a Hold.

Interact to see
Advertisement
COMPARISON
Comparison
Jul 01, 2025
Stock price -- (CDXS: $2.44 vs. NTLA: $9.38)
Brand notoriety: CDXS and NTLA are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: CDXS: 77% vs. NTLA: 57%
Market capitalization -- CDXS: $202.14M vs. NTLA: $970.58M
CDXS [@Biotechnology] is valued at $202.14M. NTLA’s [@Biotechnology] market capitalization is $970.58M. The market cap for tickers in the [@Biotechnology] industry ranges from $304.6B to $0. The average market capitalization across the [@Biotechnology] industry is $2.32B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

CDXS’s FA Score shows that 0 FA rating(s) are green whileNTLA’s FA Score has 1 green FA rating(s).

  • CDXS’s FA Score: 0 green, 5 red.
  • NTLA’s FA Score: 1 green, 4 red.
According to our system of comparison, NTLA is a better buy in the long-term than CDXS.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

CDXS’s TA Score shows that 5 TA indicator(s) are bullish while NTLA’s TA Score has 6 bullish TA indicator(s).

  • CDXS’s TA Score: 5 bullish, 3 bearish.
  • NTLA’s TA Score: 6 bullish, 3 bearish.
According to our system of comparison, NTLA is a better buy in the short-term than CDXS.

Price Growth

CDXS (@Biotechnology) experienced а +3.39% price change this week, while NTLA (@Biotechnology) price change was +1.63% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was -0.13%. For the same industry, the average monthly price growth was +32.87%, and the average quarterly price growth was +4.25%.

Reported Earning Dates

CDXS is expected to report earnings on Jul 31, 2025.

NTLA is expected to report earnings on Jul 31, 2025.

Industries' Descriptions

@Biotechnology (-0.13% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
NTLA($971M) has a higher market cap than CDXS($202M). NTLA YTD gains are higher at: -19.554 vs. CDXS (-48.847). CDXS has higher annual earnings (EBITDA): -62.28M vs. NTLA (-530.8M). NTLA has more cash in the bank: 504M vs. CDXS (59.8M). CDXS has less debt than NTLA: CDXS (59.5M) vs NTLA (119M). CDXS has higher revenues than NTLA: CDXS (49.8M) vs NTLA (45.6M).
CDXSNTLACDXS / NTLA
Capitalization202M971M21%
EBITDA-62.28M-530.8M12%
Gain YTD-48.847-19.554250%
P/E RatioN/AN/A-
Revenue49.8M45.6M109%
Total Cash59.8M504M12%
Total Debt59.5M119M50%
FUNDAMENTALS RATINGS
CDXS vs NTLA: Fundamental Ratings
CDXS
NTLA
OUTLOOK RATING
1..100
84
VALUATION
overvalued / fair valued / undervalued
1..100
46
Fair valued
27
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
9897
PRICE GROWTH RATING
1..100
8662
P/E GROWTH RATING
1..100
100100
SEASONALITY SCORE
1..100
n/an/a

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

NTLA's Valuation (27) in the Biotechnology industry is in the same range as CDXS (46) in the Chemicals Specialty industry. This means that NTLA’s stock grew similarly to CDXS’s over the last 12 months.

NTLA's Profit vs Risk Rating (100) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that NTLA’s stock grew similarly to CDXS’s over the last 12 months.

NTLA's SMR Rating (97) in the Biotechnology industry is in the same range as CDXS (98) in the Chemicals Specialty industry. This means that NTLA’s stock grew similarly to CDXS’s over the last 12 months.

NTLA's Price Growth Rating (62) in the Biotechnology industry is in the same range as CDXS (86) in the Chemicals Specialty industry. This means that NTLA’s stock grew similarly to CDXS’s over the last 12 months.

NTLA's P/E Growth Rating (100) in the Biotechnology industry is in the same range as CDXS (100) in the Chemicals Specialty industry. This means that NTLA’s stock grew similarly to CDXS’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
CDXSNTLA
RSI
ODDS (%)
N/A
N/A
Stochastic
ODDS (%)
Bearish Trend 2 days ago
85%
Bearish Trend 2 days ago
90%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bullish Trend 2 days ago
82%
MACD
ODDS (%)
Bullish Trend 2 days ago
79%
Bullish Trend 2 days ago
82%
TrendWeek
ODDS (%)
Bullish Trend 2 days ago
84%
Bullish Trend 2 days ago
79%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
83%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 6 days ago
84%
Bullish Trend 8 days ago
77%
Declines
ODDS (%)
Bearish Trend 19 days ago
84%
Bearish Trend 2 days ago
88%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
87%
Bearish Trend 2 days ago
83%
Aroon
ODDS (%)
N/A
Bullish Trend 5 days ago
90%
View a ticker or compare two or three
Interact to see
Advertisement
CDXS
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
NTLA
Daily Signalchanged days ago
Gain/Loss if bought
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
MFs / NAMEPrice $Chg $Chg %
CISGX20.66N/A
N/A
Touchstone Sands Capital Select Gr Instl
PCEQX24.04N/A
N/A
Victory Pioneer Equity Income C
HRLRX9.30N/A
N/A
Hartford Real Asset R3
IGAIX42.65N/A
N/A
American Funds Intl Gr and Inc F3
FMDCX15.38N/A
N/A
Federated Hermes Mid-Cap Index Svc

CDXS and

Correlation & Price change

A.I.dvisor indicates that over the last year, CDXS has been loosely correlated with BEAM. These tickers have moved in lockstep 49% of the time. This A.I.-generated data suggests there is some statistical probability that if CDXS jumps, then BEAM could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To CDXS
1D Price
Change %
CDXS100%
+2.09%
BEAM - CDXS
49%
Loosely correlated
+1.25%
PRAX - CDXS
49%
Loosely correlated
-2.21%
DNLI - CDXS
49%
Loosely correlated
-0.78%
CRSP - CDXS
48%
Loosely correlated
+4.15%
NTLA - CDXS
47%
Loosely correlated
-1.88%
More

NTLA and

Correlation & Price change

A.I.dvisor indicates that over the last year, NTLA has been closely correlated with VCYT. These tickers have moved in lockstep 69% of the time. This A.I.-generated data suggests there is a high statistical probability that if NTLA jumps, then VCYT could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To NTLA
1D Price
Change %
NTLA100%
-1.88%
VCYT - NTLA
69%
Closely correlated
-1.28%
CRSP - NTLA
65%
Loosely correlated
+4.15%
BEAM - NTLA
64%
Loosely correlated
+1.25%
RXRX - NTLA
56%
Loosely correlated
+0.70%
AXON - NTLA
55%
Loosely correlated
+1.14%
More